AN-2690Antifungal agent CAS# 174671-46-6 |
- Amyloid β-Peptide (10-20) (human)
Catalog No.:BCC1026
CAS No.:152286-31-2
- Beta-Amyloid (1-11)
Catalog No.:BCC1002
CAS No.:190436-05-6
- Myelin Basic Protein (68-82), guinea pig
Catalog No.:BCC1020
CAS No.:98474-59-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 174671-46-6 | SDF | Download SDF |
| PubChem ID | 11499245 | Appearance | Powder |
| Formula | C7H6BFO2 | M.Wt | 151.93 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 100 mg/mL (658.20 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 5-fluoro-1-hydroxy-3H-2,1-benzoxaborole | ||
| SMILES | B1(C2=C(CO1)C=C(C=C2)F)O | ||
| Standard InChIKey | LFQDNHWZDQTITF-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C7H6BFO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | AN-2690 is an antifungal agent. | |||||
| Targets | Trichophyton species | |||||
AN-2690 Dilution Calculator
AN-2690 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 6.582 mL | 32.9099 mL | 65.8198 mL | 131.6396 mL | 164.5495 mL |
| 5 mM | 1.3164 mL | 6.582 mL | 13.164 mL | 26.3279 mL | 32.9099 mL |
| 10 mM | 0.6582 mL | 3.291 mL | 6.582 mL | 13.164 mL | 16.4549 mL |
| 50 mM | 0.1316 mL | 0.6582 mL | 1.3164 mL | 2.6328 mL | 3.291 mL |
| 100 mM | 0.0658 mL | 0.3291 mL | 0.6582 mL | 1.3164 mL | 1.6455 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Minimum Inhibitory Concentration: 1, 1, 0.5, 0.25, and 0.25 μg/mL for T.rubrum, T.mentagrophytes, C.albicans, C.neoformans, A.fumigatus, respectivley.
AN2690 is a new boron-containing antifungal agent for the potential treatment of onychomycosis. Onychomycosis is caused mainly by dermatophytes, a class of fungus that dwells on skin, hair, and nails and is the cause of other cutaneous fungal infections such as athlete’s foot.
In vitro: AN2690 showed the most active against fungi and especially against the dermatophytes T. rubrum and T. mentagrophytes, the primary fungal pathogens causing onychomycosis. In addition, AN2690 was identified as having a unique profile of in vitro antidermatophyte activity, maintenance of this activity in the presence of keratin, and exceedingly good penetration of human nails [1].
Ex vivo: AN2690 was found to have superior penetration compared to ciclopirox, and achieves levels within and under the nail plate that suggest it has the potential to be an effective topical treatment for onychomycosis [2].
Clinical trial: The efficacy of tavaborole as a topical treatment for onychomycosis has been evaluated in two identical randomised, double-blind phase III studies, NCT01270971 (301) and NCT01302119 (302), enrolling 593 and 601 patients, respectively. Completely or almost clear nail and negative mycology was achieved in 15.3 and 17.9 % of tavaborole recipients compared with 1.5 and 3.9 % of vehicle recipients [3]
References:
[1] Baker SJ, Zhang YK, Akama T, Lau A, Zhou H, Hernandez V, Mao W, Alley MR, Sanders V, Plattner JJ. Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis. J Med Chem. 2006;49(15):4447-50.
[2] Hui X, Baker SJ, Wester RC, Barbadillo S, Cashmore AK, Sanders V, Hold KM, Akama T, Zhang YK, Plattner JJ, Maibach HI. In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. J Pharm Sci. 2007;96(10):2622-31.
[3] Markham A. Tavaborole: first global approval. Drugs. 2014;74(13):1555-8.
- Phalloidin
Catalog No.:BCC7945
CAS No.:17466-45-4
- Talnetant
Catalog No.:BCC1981
CAS No.:174636-32-9
- SB-222200
Catalog No.:BCC1926
CAS No.:174635-69-9
- SB 218795
Catalog No.:BCC7037
CAS No.:174635-53-1
- SDZ 220-040
Catalog No.:BCC6992
CAS No.:174575-40-7
- SDZ 220-581
Catalog No.:BCC1939
CAS No.:174575-17-8
- 2-Allylphenol
Catalog No.:BCC8518
CAS No.:1745-81-9
- alpha-Spinasterol glucoside
Catalog No.:BCN1120
CAS No.:1745-36-4
- Tipranavir
Catalog No.:BCC2002
CAS No.:174484-41-4
- Sanggenol A
Catalog No.:BCN3602
CAS No.:174423-30-4
- Amiloride HCl dihydrate
Catalog No.:BCC5068
CAS No.:17440-83-4
- Riluzole
Catalog No.:BCC3849
CAS No.:1744-22-5
- CH 275
Catalog No.:BCC5913
CAS No.:174688-78-9
- 2-Amino-6-methoxybenzothiazole
Catalog No.:BCC8542
CAS No.:1747-60-0
- Ginsenoside Rh4
Catalog No.:BCN3503
CAS No.:174721-08-5
- Carabrone
Catalog No.:BCN1121
CAS No.:1748-81-8
- Fmoc-Hyp(Bzl)-OH
Catalog No.:BCC3255
CAS No.:174800-02-3
- 3-Amino-4-methoxybenzamide
Catalog No.:BCC8612
CAS No.:17481-27-5
- Rabdoketone B
Catalog No.:BCN6598
CAS No.:174819-51-3
- Parishin B
Catalog No.:BCN3812
CAS No.:174972-79-3
- Parishin C
Catalog No.:BCN3813
CAS No.:174972-80-6
- Tonabersat
Catalog No.:BCC2009
CAS No.:175013-84-0
- NQDI 1
Catalog No.:BCC2404
CAS No.:175026-96-7
- O4I1
Catalog No.:BCC6542
CAS No.:175135-47-4
Tavaborole (AN-2690) for the treatment of onychomycosis of the toenail in adults.[Pubmed:24894552]
Expert Rev Anti Infect Ther. 2014 Jul;12(7):735-42.
Onychomycosis is a challenging nail disease that is difficult to treat due to the thickness and impermeability of the nail plate. At present, systemic agents are the first-line of treatment for this type of infection; however, topical treatment is recommended in milder cases (<50% involvement) or when oral treatment is contraindicated. Effective topical treatments capable of penetrating the nail plate and reaching the site of infection continue to be sought. Tavaborole, the first member of a new class of boron-containing antifungals, is a lightweight, water-soluble topical nail solution for the treatment of toenail onychomycosis. Tavaborole has a unique mechanism of action against fungal organisms and retains antifungal properties in the presence of keratin. Tavaborole 5.0% nail solution has shown a favourable safety and efficacy profile in Phase II/III clinical trials and is currently under review for licensing in the US by the US Food and Drug Administration.
AN-2690, a novel antifungal for the topical treatment of onychomycosis.[Pubmed:17668368]
Curr Opin Investig Drugs. 2007 Aug;8(8):662-8.
Schering-Plough Corp, under license from Anacor Pharmaceuticals Inc, is developing AN-2690, an antifungal agent with activity against Trichophyton species, in a topical solution formulation, for the potential treatment of onychomycosis. Phase II and IIb trials with AN-2690 are underway.
